Market closed
Prices delayed by at least 15 minutes | Prices updated on 20 May 2025, 17.32 BST | Print
Legal & General Ucits Etf Public Limited Company L&G PHARMA BREAKTHROUGH GO UCITS ETF (BIOT)
Open
$10.304
Previous close
$10.247
Trade high
$10.426
Income frequency
-
Year low
$8.964
Year high
$11.258
Replication method
Physical Full
Volume
5
Type
ETF
UCITS
Yes
Dividend yield
–
Ongoing charge
0.49
ISIN
IE00BF0H7608
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Before investing please read:
Share price
Asset allocation
| Long | Short | Net | Category | |
|---|---|---|---|---|
| Stock | 99.94 | 0.00 | 99.94 | 95.62 |
| Bond | 0.00 | 0.00 | 0.00 | 0.03 |
| Cash | 0.06 | 0.00 | 0.06 | 0.28 |
| Other | 0.00 | 0.00 | 0.00 | 4.07 |
| Property | 0.00 | 0.00 | 0.00 | -0.00 |
Top 10 holdings
| Holdings 19/05/2025 | % of assets |
|---|---|
| BioCryst Pharmaceuticals Inc | 3.84 |
| Alnylam Pharmaceuticals Inc | 3.40 |
| Pharming Group | 3.38 |
| Xeris Biopharma Holdings Inc | 3.27 |
| Catalyst Pharmaceuticals Inc | 3.19 |
| Chugai Pharmaceutical Co Ltd | 3.19 |
| Zevra Therapeutics Inc | 3.13 |
| Swedish Orphan Biovitrum AB | 3.10 |
| InnoCare Pharma Ltd | 2.96 |
| Royalty Pharma PLC Class A | 2.95 |
Investment objective
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.
Asset class
ETFMorningstar ratingTM
Morningstar sustainability ratingTM
Benchmarks
Category
Sector Equity Biotechnology
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.